Objective To investigate the short-term efficacy and adverse reactions of tislelizumab combined with nab-paclitaxel/nedaplatin in the treatment advanced lung squamous cell carcinoma.
Methods Eighty advanced lung squamous cell carcinoma patients with negative driver gene including epidermal growth factor receptor, anaplastic lymphoma kinase, and C-ROS oncogene 1 were selected and randomly divided into a simple chemotherapy group and an immunotherapy combined with chemotherapy group, with 40 cases in each group, which were treated with nab-paclitaxel/nedaplatin and tislelizumab combined with nab-paclitaxel/nedaplatin for 4 cycles, respectively.The short-term efficacy and major adverse reactions of patients in the two groups were compared.
Results In the immunotherapy combined with chemotherapy group, there was 1 case with complete remission (CR), 28 cases with partial remission (PR), 9 cases with stable disease (SD), and 2 progressive disease (PD), and the objective remission rate (ORR) was 72.5% (29/40), the disease control rate (DCR) was 95% (38/40).In the simple chemotherapy group, there was 0 case with CR, 13 cases with PR, 22 cases with SD, 5 cases with PD, and the ORR was 37.5% (13/40), DCR was 87.5% (35/40).The ORR in the immunotherapy combined with chemotherapy group was significantly higher than that in the simple chemotherapy group (P < 0.01), but there was no statistically significant difference in DCR between the two groups (P>0.05).There was no statistically significant difference in the incidence of adverse reactions such as decreased white blood cell count, decreased neutrophil count, decreased platelet count, anemia, hypoalbuminemia, elevated transaminases, fatigue, hair loss, nausea, and limb pain of patients between the two groups (P>0.05).
Conclusions Tislelizumab combined with nab-paclitaxel/nedaplatin in the treatment of advanced lung squamous cell carcinoma has better short-term efficacy than simple chemotherapy, does not increase incidence of adverse reactions in patients during the treatment period, and has good safety, which may be used as the first-line treatment for advanced lung squamous cell carcinoma patients with negative driver gene.
DownLoad: